title: Eczematous dermatitis in the setting of hyper-IgE syndrome successfully treated with omalizumab.
authors.forename: Susan
authors.initials: S
authors.lastname: Bard
authors.forename: Alexandra
authors.initials: A
authors.lastname: Paravisini
authors.forename: José Antonio
authors.initials: JA
authors.lastname: Avilés-Izquierdo
authors.forename: Eduardo
authors.initials: E
authors.lastname: Fernandez-Cruz
authors.forename: Silvia
authors.initials: S
authors.lastname: Sánchez-Ramón
mesh_terms: D000328:Adult; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D004485:Eczema / Q000188:drug therapy* / Q000209:etiology*; D005260:Female; D006801:Humans; D007073:Immunoglobulin E / Q000378:metabolism; D007589:Job Syndrome / Q000150:complications*; D000069444:Omalizumab; D016896:Treatment Outcome
chemical_list: D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab; D007073:Immunoglobulin E